<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37734871</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2056-5933</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>RMD open</Title><ISOAbbreviation>RMD Open</ISOAbbreviation></Journal><ArticleTitle>Autoantibody status according to multiparametric assay accurately estimates connective tissue disease classification and identifies clinically relevant disease clusters.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e003365</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/rmdopen-2023-003365</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Assessment of circulating autoantibodies represents one of the earliest diagnostic procedures in patients with suspected connective tissue disease (CTD), providing important information for disease diagnosis, identification and prediction of potential clinical manifestations. The purpose of this study was to evaluate the ability of multiparametric assay to correctly classify patients with multiple CTDs and healthy controls (HC), independent of clinical features, and to evaluate whether serological status could identify clusters of patients with similar clinical features.</AbstractText><AbstractText Label="METHODS">Patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Sjogren's syndrome (SjS), undifferentiated connective tissue disease (UCTD), idiopathic inflammatory myopathies (IIM) and HC were enrolled. Serum was tested for 29 autoantibodies. An XGBoost model, exclusively based on autoantibody titres was built and classification accuracy was evaluated. A hierarchical clustering model was subsequently developed and clinical/laboratory features compared among clusters.</AbstractText><AbstractText Label="RESULTS">908 subjects were enrolled. The classification model showed a mean accuracy of 60.84&#xb1;4.05% and a mean area under the receiver operator characteristic curve of 88.99&#xb1;2.50%, with significant discrepancies among groups. Cluster analysis identified four clusters (CL). CL1 included patients with typical features of SLE. CL2 included most patients with SjS, along with some SLE and UCTD patients with SjS-like features. CL4 included anti-Jo1 patients only. CL3 was the largest and most heterogeneous, including all the remaining subjects, overall characterised by low titre or lower-prevalence autoantibodies.</AbstractText><AbstractText Label="CONCLUSION">Extended multiparametric autoantibody assay allowed an accurate classification of CTD patients, independently of clinical features. Clustering according to autoantibody titres is able to identify clusters of CTD subjects with similar clinical features, independently of their final diagnosis.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Cafaro</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-1774-1916</Identifier><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Bartoloni</LastName><ForeName>Elena</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-4776-2136</Identifier><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Perugia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldini</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Franceschini</LastName><ForeName>Franco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili di Brescia, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riccieri</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, University of Rome La Sapienza, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fioravanti</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Medicine, Surgery and Neuroscience, Azienda Ospedaliera Universitaria Senese - Policlinico Le Scotte, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fornaro</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghirardello</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Medicine, University of Padua, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palterer</LastName><ForeName>Boaz</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, University of Florence, Firenze, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Infantino</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6200-4467</Identifier><AffiliationInfo><Affiliation>Laboratory of Immunology and Allergology, San Giovanni di Dio Hospital, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rigon</LastName><ForeName>Amelia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Immunology and Rheumatology, Campus Bio-Medico University, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Del Rosso</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Autoimmunity Lab, IRCCS Ospedale San Raffaele, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerli</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-4684-575X</Identifier><AffiliationInfo><Affiliation>Rheumatology Unit, Department of Medicine and Surgery, University of Perugia, Perugia, Italy roberto.gerli@unipg.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Villalta</LastName><ForeName>Danilo</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Immunology and Allergology, Santa Maria degli Angeli Hospital, Pordenone, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Bizzaro</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-4227-6983</Identifier><AffiliationInfo><Affiliation>Laboratory of Clinical Pathology, Azienda Sanitaria Universitaria Integrata di Udine, Tolmezzo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>FIRMA (Interdisciplinary Forum for the Research on Autoimmune Diseases) Collaborators</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>FIRMA Collaborators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>RMD Open</MedlineTA><NlmUniqueID>101662038</NlmUniqueID><ISSNLinking>2056-5933</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086822" MajorTopicYN="N">Disease Hotspot</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003240" MajorTopicYN="Y">Connective Tissue Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012859" MajorTopicYN="Y">Sjogren's Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Sjogren's syndrome</Keyword><Keyword MajorTopicYN="N">autoimmune diseases</Keyword><Keyword MajorTopicYN="N">lupus erythematosus, systemic</Keyword><Keyword MajorTopicYN="N">scleroderma, systemic</Keyword></KeywordList><CoiStatement>Competing interests: NB has received lecture fees from Inova Diagnostics.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Bistoni</LastName><ForeName>Onelia</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perricone</LastName><ForeName>Carlo</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Topini</LastName><ForeName>Fabiana</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sebastiano</LastName><ForeName>Manuela</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Migliorini</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Piantoni</LastName><ForeName>Silvia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cavazzana</LastName><ForeName>Ilaria</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fredi</LastName><ForeName>Micaela</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Masneri</LastName><ForeName>Stefania</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garrafa</LastName><ForeName>Emirena</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bellisai</LastName><ForeName>Francesca</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheleschi</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bacarelli</LastName><ForeName>Maria-Romana</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tampoia</LastName><ForeName>Marilina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zen</LastName><ForeName>Margherita</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parronchi</LastName><ForeName>Paola</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cammelli</LastName><ForeName>Daniele</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benucci</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Manfredi</LastName><ForeName>Mariangela</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giacomelli</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arcarese</LastName><ForeName>Luisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Querini</LastName><ForeName>Patrizia Rovere</ForeName><Initials>PR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Canti</LastName><ForeName>Valentina</ForeName><Initials>V</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>9</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>22</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>21</Day><Hour>21</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37734871</ArticleId><ArticleId IdType="pmc">PMC10514657</ArticleId><ArticleId IdType="doi">10.1136/rmdopen-2023-003365</ArticleId><ArticleId IdType="pii">rmdopen-2023-003365</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bossuyt X, De Langhe E, Borghi MO, et al. . Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases. Nat Rev Rheumatol 2020;16:715&#x2013;26. 10.1038/s41584-020-00522-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-00522-w</ArticleId><ArticleId IdType="pubmed">33154583</ArticleId></ArticleIdList></Reference><Reference><Citation>Irure-Ventura J, L&#xf3;pez-Hoyos M. The past, present, and future in antinuclear antibodies (ANA). Diagnostics 2022;12:647. 10.3390/diagnostics12030647</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics12030647</ArticleId><ArticleId IdType="pmc">PMC8946865</ArticleId><ArticleId IdType="pubmed">35328200</ArticleId></ArticleIdList></Reference><Reference><Citation>Didier K, Bolko L, Giusti D, et al. . Autoantibodies associated with connective tissue diseases: what meaning for clinicians? Front Immunol 2018;9:541. 10.3389/fimmu.2018.00541</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00541</ArticleId><ArticleId IdType="pmc">PMC5879136</ArticleId><ArticleId IdType="pubmed">29632529</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyball S, Rodziewicz M, Mendoza-Pinto C, et al. . Predicting progression from undifferentiated connective tissue disease to definite connective tissue disease: a systematic review and meta-analysis. Autoimmun Rev 2022;21:103184. 10.1016/j.autrev.2022.103184</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2022.103184</ArticleId><ArticleId IdType="pubmed">36031048</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulhearn B, Tansley SL, McHugh NJ. Autoantibodies in connective tissue disease. Best Pract Res Clin Rheumatol 2020;34:101462. 10.1016/j.berh.2019.101462</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2019.101462</ArticleId><ArticleId IdType="pubmed">31848055</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavazzana I, Richards M, Bentow C, et al. . Evaluation of a novel particle-based assay for detection of autoantibodies in idiopathic inflammatory myopathies. J Immunol Methods 2019;474:112661. 10.1016/j.jim.2019.112661</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2019.112661</ArticleId><ArticleId IdType="pubmed">31442464</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahler M, Malyavantham K, Seaman A, et al. . Profiling of myositis specific antibodies and composite scores as an aid in the differential diagnosis of autoimmune myopathies. Diagnostics 2021;11:2246. 10.3390/diagnostics11122246</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics11122246</ArticleId><ArticleId IdType="pmc">PMC8699835</ArticleId><ArticleId IdType="pubmed">34943483</ArticleId></ArticleIdList></Reference><Reference><Citation>Radin M, Cecchi I, Barinotti A, et al. . Identifying subsets of patients with undifferentiated connective tissue disease: results from a prospective, real-world experience using particle-based multi-analyte technology. Autoimmun Rev 2023;22:103298. 10.1016/j.autrev.2023.103298</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2023.103298</ArticleId><ArticleId IdType="pubmed">36796708</ArticleId></ArticleIdList></Reference><Reference><Citation>Radin M, Foddai S, Cecchi I, et al. . Improving the clinical accuracy in patients with antiphospholipid antibodies using anti-phosphatidylserine/prothrombin and anti-Beta2 glycoprotein I domain and particle-based multi-analyte technology. Thromb Res 2021;202:100&#x2013;3. 10.1016/j.thromres.2021.03.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2021.03.019</ArticleId><ArticleId IdType="pubmed">33798802</ArticleId></ArticleIdList></Reference><Reference><Citation>Radin M, Cecchi I, Foddai SG, et al. . Validation of the particle-based multi-analyte technology for detection of anti-phosphatidylserine/prothrombin antibodies. Biomedicines 2020;8:622. 10.3390/biomedicines8120622</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines8120622</ArticleId><ArticleId IdType="pmc">PMC7766094</ArticleId><ArticleId IdType="pubmed">33348782</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards M, Garc&#xed;a-De La Torre I, Gonz&#xe1;lez-Bello YC, et al. . Autoantibodies to Mi-2 alpha and Mi-2 beta in patients with idiopathic inflammatory myopathy. Rheumatology 2019;58:1655&#x2013;61. 10.1093/rheumatology/kez092</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kez092</ArticleId><ArticleId IdType="pubmed">30938432</ArticleId></ArticleIdList></Reference><Reference><Citation>Sciascia S, Radin M, Ramirez C, et al. . Evaluation of novel assays for the detection of autoantibodies in antiphospholipid syndrome. Autoimmun Rev 2020;19:102641. 10.1016/j.autrev.2020.102641</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102641</ArticleId><ArticleId IdType="pubmed">32801044</ArticleId></ArticleIdList></Reference><Reference><Citation>Villalta D, Seaman A, Tiongson M, et al. . Evaluation of a novel extended automated particle-based multi-analyte assay for the detection of autoantibodies in the diagnosis of primary biliary cholangitis. Clin Chem Lab Med 2020;58:1499&#x2013;507. 10.1515/cclm-2020-0122</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2020-0122</ArticleId><ArticleId IdType="pubmed">32286240</ArticleId></ArticleIdList></Reference><Reference><Citation>Bizzaro N, Villalta D, Bini V, et al. . Multiparametric autoantibody analysis: a new paradigm for the diagnosis of connective tissue diseases. Arthritis Res Ther 2022;24:278. 10.1186/s13075-022-02980-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-022-02980-x</ArticleId><ArticleId IdType="pmc">PMC9783721</ArticleId><ArticleId IdType="pubmed">36564813</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, et al. . 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019;71:1400&#x2013;12. 10.1002/art.40930</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40930</ArticleId><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference><Reference><Citation>Lilleker JB, Vencovsky J, Wang G, et al. . Response to: 'Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria' by Cavagna et al. Ann Rheum Dis 2018;77:e51. 10.1136/annrheumdis-2017-212382</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-212382</ArticleId><ArticleId IdType="pubmed">29259048</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiboski CH, Shiboski SC, Seror R, et al. . American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sj&#xf6;gren&#x2019;s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol 2017;69:35&#x2013;45. 10.1002/art.39859</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39859</ArticleId><ArticleId IdType="pmc">PMC5650478</ArticleId><ArticleId IdType="pubmed">27785888</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Hoogen F, Khanna D, Fransen J, et al. . Classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747&#x2013;55. 10.1136/annrheumdis-2013-204424</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-204424</ArticleId><ArticleId IdType="pubmed">24092682</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosca M, Neri R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol 1999;17:615&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">10544849</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Kim MY, Kalunian KC, et al. . Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550&#x2013;8. 10.1056/NEJMoa051135</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa051135</ArticleId><ArticleId IdType="pubmed">16354891</ArticleId></ArticleIdList></Reference><Reference><Citation>Seror R, Ravaud P, Bowman SJ, et al. . EULAR Sjogren&#x2019;s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren&#x2019;s syndrome. Ann Rheum Dis 2010;69:1103&#x2013;9. 10.1136/ard.2009.110619</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2009.110619</ArticleId><ArticleId IdType="pmc">PMC2937022</ArticleId><ArticleId IdType="pubmed">19561361</ArticleId></ArticleIdList></Reference><Reference><Citation>Elm E von, Altman DG, Egger M, et al. . The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335:806&#x2013;8. 10.1136/bmj.39335.541782.AD</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39335.541782.AD</ArticleId><ArticleId IdType="pmc">PMC2034723</ArticleId><ArticleId IdType="pubmed">17947786</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenti MV, Rossi CM, Melazzini F, et al. . Seronegative autoimmune diseases: a challenging diagnosis. Autoimmun Rev 2022;21:103143. 10.1016/j.autrev.2022.103143</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2022.103143</ArticleId><ArticleId IdType="pubmed">35840037</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiriakidou M, Ching CL. Systemic lupus erythematosus. Ann Intern Med 2020;172:ITC81&#x2013;96. 10.7326/AITC202006020</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/AITC202006020</ArticleId><ArticleId IdType="pubmed">32479157</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi D, Elefante E, Schilir&#xf2; D, et al. . One year in review 2022: systemic lupus erythematosus. Clin Exp Rheumatol 2022;40:4&#x2013;14. 10.55563/clinexprheumatol/nolysy</Citation><ArticleIdList><ArticleId IdType="doi">10.55563/clinexprheumatol/nolysy</ArticleId><ArticleId IdType="pubmed">35088691</ArticleId></ArticleIdList></Reference><Reference><Citation>Cafaro G, Gerli R, Bartoloni E. Association between glandular infiltrate and leukopenia in Sj&#xf6;gren syndrome (SS): data from the Italian research group on SS (GRISS). J Rheumatol 2020;47:1840&#x2013;1. 10.3899/jrheum.200328</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.200328</ArticleId><ArticleId IdType="pubmed">32934138</ArticleId></ArticleIdList></Reference><Reference><Citation>Cafaro G, Perricone C, Baldini C, et al. . Significance of anti-La/SSB antibodies in primary Sj&#xf6;gren&#x2019;s syndrome patients with combined positivity for anti-Ro/SSA and salivary gland biopsy. Clin Exp Rheumatol 2020;38 Suppl 126:53&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">33095137</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo J, Zhang Y, Chen J-Q, et al. . Distinct clinical phenotypes of primary Sj&#xf6;gren&#x2019;s syndrome differ by onset age: a retrospective study of 742 cases and review of the literature. Clin Exp Rheumatol 2022;40:2373&#x2013;80. 10.55563/clinexprheumatol/b4z1qu</Citation><ArticleIdList><ArticleId IdType="doi">10.55563/clinexprheumatol/b4z1qu</ArticleId><ArticleId IdType="pubmed">36441650</ArticleId></ArticleIdList></Reference><Reference><Citation>Manfr&#xe8; V, Chatzis LG, Cafaro G, et al. . Sj&#xf6;gren&#x2019;s syndrome: one year in review 2022. Clin Exp Rheumatol 2022;40:2211&#x2013;24. 10.55563/clinexprheumatol/43z8gu</Citation><ArticleIdList><ArticleId IdType="doi">10.55563/clinexprheumatol/43z8gu</ArticleId><ArticleId IdType="pubmed">36541236</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavagna L, Nu&#xf1;o L, Scir&#xe8; CA, et al. . Clinical spectrum time course in anti Jo-1 positive Antisynthetase syndrome: results from an international retrospective multicenter study. Medicine (Baltimore) 2015;94:e1144. 10.1097/MD.0000000000001144</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000001144</ArticleId><ArticleId IdType="pmc">PMC4616698</ArticleId><ArticleId IdType="pubmed">26266346</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>